A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Name: A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Published: 2014
License: Public Domain

Merck Sharp & Dohme LLC · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

melanoma

melanoma, solid tumors, programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), programmed cell death 1 ligand 2 (pdl2, pd-l2), interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Related documents